Researchers from First People's Hospital Detail New Studies and Findings in the Area of Cancer (Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio As Potential Predictive Markers of Treatment Response In Cancer Patients Treated With...).

A recent report from researchers at First People's Hospital in Hunan, China explores the potential of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) as predictive markers for treatment response in cancer patients receiving immune checkpoint inhibitors (ICIs). The study analyzed 40 papers and found that low NLR and PLR were associated with higher objective response rates and disease control rates, while high NLR and PLR were linked to a higher probability of disease progression. The researchers concluded that these ratios could be used alongside other markers to determine treatment efficacy in immunotherapy. This research provides valuable insights for clinicians and researchers in the field of cancer treatment. [Extracted from the article]